| miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors S Sharma, GM Pavlasova, V Seda, KA Cerna, E Vojackova, D Filip, ... Blood, The Journal of the American Society of Hematology 137 (18), 2481-2494, 2021 | 52 | 2021 |
| Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels G Pavlasova, M Borsky, V Svobodova, J Oppelt, K Cerna, J Novotna, ... Leukemia 32 (9), 2028-2031, 2018 | 47 | 2018 |
| IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib V Sandova, GM Pavlasova, V Seda, KA Cerna, S Sharma, V Palusova, ... Haematologica 106 (11), 2995, 2021 | 21 | 2021 |
| Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia K Zaprazna, K Reblova, V Svobodova, L Radova, V Bystry, J Baloun, ... Annals of hematology 98, 423-435, 2019 | 4 | 2019 |
| miR-29-TRAF4 axis is a novel regulator of CD40 signaling in malignant B cells S Sharma, V Seda, E Vojackova, GM Pavlasova, D Filip, L Ondrisova, ... Cancer Research 81 (13_Supplement), 2368-2368, 2021 | | 2021 |
| The biology of miRNAs in B cell malignancies and their use as biomarkers. D Filip, S Sharma, K Musilová, K Amruz Černá, L Košťálová, V Šeda, ... | | 2021 |
| The role of long non-coding RNAs in the BCR-mediated activation of malignant B cells. P Faria Zeni, M Medková, K Trachtová, V Šeda, S Sharma, J Večeřa, ... | | 2021 |
| Regulation of BCR signaling during therapy in chronic lymphocytic leukemia. L Košťálová, V Šeda, L Ondrišová, E Vojáčková, D Filip, V Šandová, ... | | 2020 |
| CD20 in the context of microenvironmental interactions of malignant B cells: Implications for targeted therapy. G Mladonická Pavlasová, V Šandová, M Borský, J Oppelt, V Šeda, ... | | 2019 |
| The surprising role of microRNAs in the DNA damage and B cell receptor signalling in malignant B cells K Amruz Černá, K Musilová, G Mladonická Pavlasová, V Šeda, J Oppelt, ... | | 2019 |
| CD20 supports BCR signaling in an intra-clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR-proficient B cells in vivo G Pavlasova, M Borsky, V Svobodova, J Oppelt, K Cerna, J Novotna, ... Cancer Research 78 (13 Supplement), 1012-1012, 2018 | | 2018 |
| Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels G Mladonická Pavlasová, M Borský, V Šandová, J Oppelt, K Amruz Černá, ... | | 2018 |
| Abstract A34: The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies G Pavlasova, K Musilova, V Seda, K Cerna, E Vojackova, V Svobodova, ... Molecular Cancer Therapeutics 16 (10 Supplement), A34-A34, 2017 | | 2017 |
| Differential expression of microRNAs in transformation of follicular lymphoma to diffuse large B cell lymphoma K Musilova, G Pavlasova, V Seda, E Vojackova, K Cerna, V Svobodova, ... Cancer Research 77 (13 Supplement), 1479-1479, 2017 | | 2017 |
| BCR SIGNALLING PROFICIENT CHRONIC LYMPHOCYTIC LEUKAEMIA B CELLS ARE PRONE TO RITUXIMAB MEDIATED ELIMINATION IN VIVO G Pavlasova, M Borsky, V Svobodova, K Musilova, K Cerna, V Seda, ... HAEMATOLOGICA 102, 412-412, 2017 | | 2017 |
| Molekulární podstata UPR (Unfolded Protein Response) V Svobodová Masarykova univerzita, Přírodovědecká fakulta, 2013 | | 2013 |
| IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kd inhibitor idelalisib S Sharma, V Palusova, Y Brychtova, S Pospisilova, SM Fernandes | | |
